Over the past three decades, advances in chemotherapy, including platinum- and taxane-based regimens and intraperitoneal chemotherapy, have improved survival among women with advanced ovarian cancer (OC) ([Alberts *et al*, 1996](#bib1){ref-type="other"}; [Markman *et al*, 2001](#bib33){ref-type="other"}; [Armstrong *et al*, 2006](#bib3){ref-type="other"}).

Failure to receive standard therapy is associated with decreased survival ([Tingulstad *et al*, 2003](#bib43){ref-type="other"}). However, not all patients, especially elderly patients, are offered optimal chemotherapy. A study by our group found that although 83% of elderly patients with stage III and IV disease received some form of chemotherapy, only 52% received platinum-based therapy. Factors associated with non-platinum-based treatment included older age, nonwhite ethnicity and number of comorbid medical conditions ([Sundararajan *et al*, 2002](#bib42){ref-type="other"}). Provider type and surgical volume have also been shown to influence the likelihood of receiving chemotherapy ([Schrag *et al*, 2006](#bib40){ref-type="other"}).

Dose-intense treatment (higher mg per m^2^ per unit of time) has been found to improve the survival of patients with breast cancer and other cancers ([Hudis *et al*, 1999](#bib28){ref-type="other"}; [Citron *et al*, 2003](#bib9){ref-type="other"}). But most clinical trials among patients with OC have failed to show a survival advantage of dose-intense regimens ([McGuire *et al*, 1995](#bib34){ref-type="other"}, [1996](#bib35){ref-type="other"}; [Conte *et al*, 1996](#bib12){ref-type="other"}; [Jakobsen *et al*, 1997](#bib29){ref-type="other"}; [McGuire, 1997](#bib36){ref-type="other"}; [Gore *et al*, 1998](#bib22){ref-type="other"}). For example, the Gynecologic Oncology Group (GOG) compared patients treated with eight cycles of standard dose cisplatin and cyclophosphamide to those receiving four cycles of high-dose therapy. Although response rates and survival were similar, toxicity was more common in the dose-intense group than in the standard dose group ([McGuire *et al*, 1995](#bib34){ref-type="other"}).

The optimal timing of chemotherapy initiation in the postoperative period and the ideal duration of treatment (including number of cycles) have not been determined. However, in most clinical trials, patients are required to register within 6 weeks of surgery. Studies examining the time from surgery to initiation of adjuvant chemotherapy have reported varied results; however, some have suggested that prolonging the interval between surgery and the initiation of adjuvant chemotherapy adversely affects survival ([Omura *et al*, 1989](#bib37){ref-type="other"}; [Warwick *et al*, 1995](#bib46){ref-type="other"}; [Flynn *et al*, 2002](#bib18){ref-type="other"}; [Gadducci *et al*, 2005](#bib19){ref-type="other"}; [Paulsen *et al*, 2006a](#bib38){ref-type="other"}; [Aletti *et al*, 2007](#bib2){ref-type="other"}).

The goal of our study was to analyse the association of demographic and clinical factors with delay in initiation of chemotherapy and early termination of chemotherapy in women with advanced OC and to evaluate the association of those aspects of treatment with survival.

MATERIALS AND METHODS
=====================

Data source
-----------

For this analysis, we obtained data from two linked databases. The National Cancer Institute\'s Surveillance, Epidemiology, and End Results (SEER) cancer registry collects data on cancer patients representing 26% of the US population from five state-based and seven county-based cancer registries. The SEER database includes patient demographics; cancer organ/site, histology, stage and other clinical markers; and primary treatment. The Center for Medicare and Medicaid Services (CMS) maintains a database of patients on Medicare with diagnosis codes and procedural billing codes for their medical expenses. The SEER-Medicare linked database, initiated in 1991, has been previously described and validated ([Klabunde *et al*, 2000](#bib31){ref-type="other"}; [Warren *et al*, 2002](#bib45){ref-type="other"}).

Patient selection criteria
--------------------------

Eligible patients were those 65 years of age or older at diagnosis with a first primary epithelial OC, American Joint Cancer Committee (AJCC) stage III or IV, and diagnosed between 1 January 1991 and 31 December 2002.

Patients were included in the analysis if they received at least one cycle of chemotherapy within 12 months after surgical resection, survived for at least 7 months after initiating chemotherapy and received chemotherapy continuously for ⩽7 months. Patients who received chemotherapy for \>7 months may have had refractory disease, which is not the focus of this study. Patients who did not receive primary, cancer-directed surgery at all or prior to receiving chemotherapy were excluded. Patients who were members of a Medicare health maintenance organization (HMO) at any time from 12 months before to 8 months after their diagnosis of OC also were excluded, because HMOs do not report claims for individual expenses to Medicare. Other exclusion criteria were gaps in Medicare Part A or B coverage during the study period, histologically unconfirmed diagnosis, non-epithelial tumour histology and tumour of low malignant potential. Among 3585 patients who underwent surgery for OC, 1021 did not receive chemotherapy within 12 months of surgery and were excluded.

For each eligible patient, we obtained data on age group at diagnosis, year of diagnosis, race/ethnicity, marital status, tumour stage (III or IV), tumour histology (serous, mucinous, endometrioid, other), comorbidity score, residence (metropolitan or non-metropolitan), type of hospital (teaching or non-teaching) in which they were diagnosed, and socioeconomic indicators for their census tract/zip code of residence from SEER. Comorbidity data and treatment data were obtained from Medicare.

Treatment delay
---------------

The time, in weeks, from surgical resection until delivery of the first cycle of chemotherapy was calculated for each patient. Based on the inclusion criteria for GOG clinical trials, we categorised patients who initiated chemotherapy ⩽6 weeks after surgical resection as receiving timely treatment, and patients who initiated treatment \>6 weeks after surgery as receiving delayed treatment. In addition, we categorised patients by 4-week intervals to determine the potential benefit of early initiation of treatment.

Early termination of treatment
------------------------------

Only women who initiated chemotherapy within 12 weeks after surgery were included in the analysis of early termination of therapy. Treatment duration was defined as the number of days between the first and last claim for chemotherapy. Subjects were categorised as receiving treatment for ⩽3 months or 3--7 months.

Treatment
---------

We used the International Classification of Diseases, 9th revision, Clinical Modification (ICD-9-CM) codes and AMA Current Procedural Terminology Codes (CPT) to categorise surgical procedures for OC. Among patients who underwent OC-directed surgery, we identified patients who received any cytotoxic chemotherapy in a physician\'s office or in an outpatient hospital unit.

Socioeconomic status
--------------------

An aggregate socioeconomic status (SES) score was generated from a hierarchy of income data from the 2000 Census, according to the method adapted from Nancy Krieger ([Bach *et al*, 1999](#bib4){ref-type="other"}). Patients were ranked on a 1--5 scale, with 1 as the lowest value, based on a formula that incorporated as many of the following variables as were available: median income in the census tract of residence, median income in the zip code of residence, census tract per capita income, zip code per capita income. Patients for whom all values were missing were assigned to the lowest SES category.

Comorbid disease
----------------

To assess the prevalence of comorbid disease in our cohort, we used the Charlson comorbidity index as adapted by Klabunde *et al* ([Deyo *et al*, 1992](#bib13){ref-type="other"}; [Klabunde *et al*, 2000](#bib31){ref-type="other"}, [2002](#bib32){ref-type="other"}). Medicare inpatient and outpatient claims were searched for ICD-9-CM diagnostic codes that indicated a history of myocardial infarction, congestive heart failure, peripheral vascular disease, cerebrovascular disease, dementia, chronic pulmonary disease, connective tissue disease, mild-to-severe liver disease, diabetes with or without end-organ damage, hemiplegia, moderate-to-severe renal disease, or acquired immunodeficiency syndrome in the Medicare files from 12 months before to 1 month after the diagnosis of cancer. Each condition was weighted, and patients were assigned a score based on the Klabunde--Charlson index ([Klabunde *et al*, 2000](#bib31){ref-type="other"}, [2002](#bib32){ref-type="other"}).

Survival
--------

Survival was calculated as the number of months from the cancer diagnosis date to the Medicare date of death. Ovarian-cancer-specific survival was defined as the number of months from the cancer diagnosis to date of death from OC. Patients who survived past the end of follow-up (31 December 2003) were censored and contributed the time from their diagnosis date to the end of follow-up to the analyses of overall survival.

Statistical analysis
--------------------

The *χ*^2^ test was used to compare the frequency distributions of categorical variables. All hypothesis tests were two-sided. In a logistic regression analysis, we modelled the predictors of delayed treatment. In Cox proportional hazards analyses, we modelled the overall mortality hazard ratios (HRs) of patients who received delayed treatment compared to other patients, controlling for the other predictor variables. We also generated adjusted Kaplan--Meier curves of overall survival by delayed *vs* timely start of chemotherapy and for termination in ⩽3 *vs* \>3 months.

RESULTS
=======

We identified 6047 individuals with stages III--IV epithelial OC from the SEER-Medicare database. A total of 3585 women underwent OC-directed surgery. Among these women, 2558 (71%) received at least one cycle of chemotherapy. [Table 1](#tbl1){ref-type="table"} shows their demographic characteristics.

Treatment delay
---------------

Among the 2558 patients who received chemotherapy, 1712 (67%) began treatment within 6 weeks of surgery, while 846 (33%) initiated chemotherapy \>6 weeks after surgery. The median time to the initiation of chemotherapy was 5 weeks after surgery. In univariate analysis, advanced age, black race, being unmarried and an increased number of comorbid conditions were associated with delayed treatment; living in a metropolitan area, treatment at a teaching hospital, advanced stage, histology, SES and year of diagnosis were not associated with delayed treatment ([Table 1](#tbl1){ref-type="table"}). In a logistic regression model, advanced age, black race and marital status were associated with delayed initiation of chemotherapy ([Table 2](#tbl2){ref-type="table"}). Black patients were more than twice as likely as white patients to delay initiation of chemotherapy (*P*=0.0007).

In a Cox proportional hazards regression model, treatment delay was associated with a 13% increase in overall mortality (HR=1.13; 95% CI, 1.03--1.25) ([Table 2](#tbl2){ref-type="table"}). Advanced age at diagnosis, stage IV disease, mucinous histology and increasing medical comorbidities were also associated with an increased risk of death. Treatment at a teaching hospital was associated with a lower mortality.

The median survival for women who initiated treatment within 6 weeks was 34 months compared to 28 months for patients who began therapy more than 6 weeks after surgery. Kaplan--Meier analysis demonstrated that women who initiated treatment \>6 weeks after had poorer overall (*P*\<0.0001) and OC-specific (*P*=0.009) survival than women who did not delay treatment ([Figure 1](#fig1){ref-type="fig"}). However, initiating therapy \<4 weeks postoperatively provided no survival benefit from doing so at 4--8 weeks (*P*=0.27).

Early termination of treatment
------------------------------

Among the 1932 patients who initiated therapy within 12 weeks after surgery ([Table 3](#tbl3){ref-type="table"}), the median duration of therapy was 3.5 months or ∼15 weeks, consistent with our assumption that if standard treatment with six cycles were administered every 3 weeks, it would take about 15 weeks from initiation to completion of therapy. A total of 714 patients (37%) were treated for ⩽3 months and 1218 (63%) for 3--7 months. In univariate analysis, race, type of hospital and number of medical comorbidities were associated with duration of treatment ([Table 3](#tbl3){ref-type="table"}). In a logistic regression model treatment at a teaching hospital was associated with receiving 3--7 months of therapy ([Table 4](#tbl4){ref-type="table"}).

In a Cox proportional hazards regression model, patients treated for 3--7 months had 16% lower mortality than patients treated for ⩽3 months (HR=0.84; 95% CI, 0.75--0.94) ([Table 4](#tbl4){ref-type="table"}). The median survival was 38 months for those treated for 3--7 months compared to 33 months for women treated for \<3 months. [Figure 2](#fig2){ref-type="fig"} displays the Kaplan--Meier plots of survival as a function of treatment duration. Treatment for ⩽3 months was associated with poorer overall (*P*\<0.0001) and cancer-specific (*P*\<0.0001) survival than longer treatment.

DISCUSSION
==========

Our findings demonstrate that among women with advanced OC who receive chemotherapy, substantial variability exists in the delivery of this treatment. Women who initiated therapy more than 6 weeks after surgery and patients who received an abbreviated course of treatment for less than 3 months were more likely to die even after adjustment for other known prognostic factors. Although waiting longer than 6 weeks to initiate therapy was associated with poorer survival, starting within 4 weeks after surgery was not associated with better survival.

The timing of initiation of adjuvant chemotherapy and survival has been studied in a variety of settings, with varied results. Among patients with lymph node-positive, oestrogen receptor-negative breast tumours, initiation of chemotherapy within 4 weeks was associated with improved survival ([Colleoni *et al*, 2000](#bib11){ref-type="other"}). Elderly patients with early-stage breast cancer appeared to derive no benefit from early initiation of chemotherapy, but long treatment initiation delays were associated with increased mortality ([Hershman *et al*, 2006b](#bib27){ref-type="other"}). Other adjuvant breast cancer trials have also failed to detect a benefit from early initiation of therapy ([Shannon *et al*, 2003](#bib41){ref-type="other"}; [Cold *et al*, 2005](#bib10){ref-type="other"}). Our group recently reported the effect of treatment delay in patients with stage III colon cancer. In a multivariate analysis, delaying initiation of treatment for over 3 months was associated with a 50% increase in colon cancer-specific mortality ([Hershman *et al*, 2006a](#bib25){ref-type="other"}).

A theoretical basis for early administration of cytotoxic agents has been demonstrated in several preclinical models. In a mouse mammary tumour model, removal of the primary lesions resulted in increased tumour proliferation and, therefore, more susceptibility to cytotoxic chemotherapeutic agents. In these studies, early perioperative initiation of chemotherapy resulted in better tumour control than delayed therapy ([Fisher *et al*, 1983](#bib17){ref-type="other"}; [Bell *et al*, 1988](#bib5){ref-type="other"}).

A prospective GOG trial of adjuvant cisplatin and cyclophosphamide with or without doxorubicin examined the effect of delay in the initiation of treatment and outcome for 349 patients with stage III OC. The investigators categorised patients by week of initiation and found that women who began therapy at week 6 had worse survival than those treated earlier ([Omura *et al*, 1989](#bib37){ref-type="other"}). In a multicentre retrospective Italian report as well as a single institution study from the United States, timing to initiation of treatment had no effect on survival ([Gadducci *et al*, 2005](#bib19){ref-type="other"}; [Aletti *et al*, 2007](#bib2){ref-type="other"}). In a separate study of 472 patients, [Flynn *et al* (2002)](#bib18){ref-type="other"} found that women who started chemotherapy within 3 weeks after surgery had a shorter progression-free interval than women who started later. However, the early treatment group had a significantly higher percentage of patients with large volume residual tumours.

Our study differs from previous reports in several respects. We compared patients who initiated treatment 6 weeks or earlier after surgery with women who began treatment later. The majority of previous studies divided patients by much shorter time intervals. Patients in the GOG trial were all treated within 6 weeks and stratified by weekly intervals ([Omura *et al*, 1989](#bib37){ref-type="other"}). Similarly, the majority of patients in the other reports were treated relatively early ([Flynn *et al*, 2002](#bib18){ref-type="other"}; [Gadducci *et al*, 2005](#bib19){ref-type="other"}; [Aletti *et al*, 2007](#bib2){ref-type="other"}). [Aletti *et al* (2007)](#bib2){ref-type="other"} and the Multicenter Italian Study Group divided patients into quartiles, the last quartile consisting of patients treated \>34 days after surgery ([Omura *et al*, 1989](#bib37){ref-type="other"}; [Gadducci *et al*, 2005](#bib19){ref-type="other"}). These data suggest that very early treatment may be of limited clinical benefit but that prolonged delays in treatment initiation may have a deleterious effect on survival. Half of our elderly subjects were treated 5 weeks or more after surgery. The relative contributions of patient and physician preferences, performance status and duration of recovery from surgery to delay are unknown.

We found that women treated with chemotherapy for a total duration of \<3 months had a 16% higher risk of dying than women treated longer. Similar findings have been reported in both adjuvant colon cancer and breast cancer treatment ([Tingulstad *et al*, 2003](#bib43){ref-type="other"}; [Hershman *et al*, 2005](#bib26){ref-type="other"}). Previous reports have found that patients treated at teaching hospitals were more likely than those at non-teaching hospitals to receive a full six cycles of therapy ([Tingulstad *et al*, 2003](#bib43){ref-type="other"}; [Paulsen *et al*, 2006b](#bib39){ref-type="other"}). In a patterns of care study, [Paulsen *et al* (2006b)](#bib39){ref-type="other"} demonstrated that 43% of patients at non-teaching hospitals but only 16% of patients at teaching hospitals received \<6 courses of therapy. Notably, only 72% of women at non-teaching hospitals received some form of chemotherapy. In our cohort, 32% of patients at non-teaching hospitals compared to 38% at teaching hospitals received \<3 months of therapy. While statistically significant, the difference was quite small.

This study is one of the first to examine age and racial differences in the quality of chemotherapy delivery in women with OC. Advancing age was associated with a progressively greater risk of delay in initiation of chemotherapy. Previous work has suggested that elderly OC patients are less likely to receive chemotherapy than younger patients and that those who do are often treated with less-aggressive regimens ([Bruchim *et al*, 2002](#bib7){ref-type="other"}; [Efstathiou *et al*, 2007](#bib15){ref-type="other"}). A recent study of breast cancer patients suggested that black patients and elderly patients were more likely to receive nonstandard treatment regimen ([Griggs *et al*, 2007](#bib23){ref-type="other"}). Similarly, in our series, black patients were more likely to experience a delay in starting chemotherapy. Previous univariate analysis of SEER data suggested that black patients were less likely to receive guideline-based chemotherapy ([Harlan *et al*, 2003](#bib24){ref-type="other"}).

Treatment quality is influenced by physician-related factors. Several studies have demonstrated superior outcomes for women treated by surgical specialists and high-volume surgeons ([Junor *et al*, 1999](#bib30){ref-type="other"}; [Carney *et al*, 2002](#bib8){ref-type="other"}; [Elit *et al*, 2002](#bib16){ref-type="other"}; [Earle *et al*, 2006](#bib14){ref-type="other"}; [Goff *et al*, 2006](#bib21){ref-type="other"}, [2007](#bib20){ref-type="other"}; [Paulsen *et al*, 2006b](#bib39){ref-type="other"}; [Vernooij *et al*, 2007](#bib44){ref-type="other"}). In an analysis of over 3000 patients, those operated on by gynaecologic oncologists were more likely to undergo surgical cytoreduction and had improved outcomes ([Earle *et al*, 2006](#bib14){ref-type="other"}). Likewise, patients who were operated on at high-volume facilities and teaching hospitals are more likely to undergo comprehensive surgical staging and cytoreduction, and have better survival than those treated at smaller and non-teaching hospitals ([Tingulstad *et al*, 2003](#bib43){ref-type="other"}; [Paulsen *et al*, 2006b](#bib39){ref-type="other"}; [Vernooij *et al*, 2007](#bib44){ref-type="other"}). However, many patients with OC do not receive care from surgical specialists or at large volume facilities ([Carney *et al*, 2002](#bib8){ref-type="other"}; [Bristow *et al*, 2004](#bib6){ref-type="other"}).

Although the patients in the SEER-Medicare database are representative of elderly patients treated in the United States, the database has a number of limitations. It does not include patients under the age of 65 years. It does not include data on important prognostic factors, such as the volume of residual tumour at the initiation of chemotherapy; the actual doses delivered (we used duration of therapy as a surrogate for dose intensity); patient and physician preferences, which are critically important to both the initiation and continuation of chemotherapy; and performance status. Although we used age and medical comorbidities as surrogates, these variables are unable to compensate fully for the lack of performance status information.

Our findings indicate that delayed treatment initiation and early chemotherapy discontinuation were common in elderly women with OC, and that these variations in treatment delivery are associated with survival. Although early initiation of chemotherapy appears to confer little benefit, prolonged delays in beginning treatment and early discontinuation of treatment are associated with poor outcomes. Prospective studies of factors that influence the quality of care in women with OC are needed, but until such studies are completed, efforts should be made to facilitate prompt initiation and full completion of adjuvant chemotherapy.
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###### 

Univariate associations between weeks to initiation of chemotherapy and demographic and clinical variables

                                     **⩽6**   **6**    **Total**                            
  --------------------------------- -------- -------- ----------- -------- ------ --------- --------
                                      1712    \(67\)      846      \(33\)   2558   \(100\)   
  *Age at diagnosis*                                                                        
   65--69                             475     \(28\)      203      \(24\)   678    \(27\)    
   70--74                             593     \(35\)      259      \(31\)   852    \(33\)    
   75--79                             429     \(25\)      242      \(29\)   671    \(26\)    
   80+                                215     \(13\)      142      \(17\)   357    \(14\)   0.0002
                                                                                             
  *Race*                                                                                    
   White                              1598    \(94\)      756      \(89\)   2354   \(92\)    
   Black                               42     \(2\)       44       \(5\)     86     \(3\)    
   Other                               72     \(4\)       46       \(5\)    118     \(5\)   0.0004
                                                                                             
  *Live in metropolitan location*                                                           
   No                                 159     \(9\)       67       \(8\)    226     \(9\)    
   Yes                                1553    \(91\)      779      \(92\)   2332   \(91\)   0.25
                                                                                             
  *Marital status*                                                                          
   No                                 752     \(44\)      426      \(50\)   1178   \(46\)    
   Yes                                916     \(54\)      395      \(47\)   1311   \(51\)    
   Unknown                             44     \(3\)       25       \(3\)     69     \(3\)   0.005
                                                                                             
  *Teaching hospital*                                                                       
   No                                 302     \(18\)      166      \(20\)   468    \(18\)    
   Yes                                1410    \(82\)      680      \(80\)   2090   \(82\)   0.22
                                                                                             
  *Histology*                                                                               
   Serous                             1066    \(62\)      508      \(60\)   1574   \(62\)    
   Mucinous                            58     \(3\)       40       \(5\)     98     \(4\)    
   Endometrioid                       150     \(9\)       59       \(7\)    209     \(8\)    
   Other                              438     \(26\)      239      \(28\)   677    \(26\)   0.077
                                                                                             
  *Stage*                                                                                   
   III                                1065    \(62\)      530      \(63\)   1595   \(62\)    
   IV                                 647     \(38\)      316      \(37\)   963    \(38\)   0.83
                                                                                             
  *No. of comorbid conditions*                                                              
   0                                  894     \(52\)      403      \(48\)   1297   \(51\)    
   1                                  475     \(28\)      241      \(28\)   716    \(28\)    
   ⩾2                                 343     \(20\)      202      \(24\)   545    \(21\)   0.03
                                                                                             
  *SES*                                                                                     
   Lowest quintile                    318     \(19\)      156      \(18\)   474    \(19\)    
   Second quintile                    324     \(19\)      161      \(19\)   485    \(19\)    
   Third quintile                     343     \(20\)      172      \(20\)   515    \(20\)    
   Fourth quintile                    338     \(20\)      174      \(21\)   512    \(20\)    
   Fifth quintile                     389     \(23\)      183      \(22\)   572    \(22\)   0.97

###### 

Association of demographic and clinical characteristics with initiation of chemotherapy \>6 weeks after surgery and overall mortality hazard ratios in patients with ovarian cancer by time to initiation of chemotherapy

                                   **\>6 weeks to initiation of treatment**   **Overall mortality**
  ------------------------------- ------------------------------------------ -----------------------
  *Initiation of treatment*                                                  
   ⩽6 weeks                                          ---                            Referent
   \>6 weeks                                         ---                      1.13 (1.03--1.25)^\*^
                                                                                         
  *Age at diagnosis*                                                         
   65--70                                          Referent                         Referent
   70--74                                     1.02 (0.81--1.27)               1.23 (1.09--1.38)^\*^
   75--79                                   1.31 (1.04--1.65)^\*^             1.27 (1.12--1.44)^\*^
   80+                                        1.47 (1.11--1.93)               1.45 (1.24--1.68)^\*^
                                                                                         
  *Race*                                                                     
   White                                           Referent                         Referent
   Black                                    2.24 (1.42--3.52)^\*^               0.80 (0.62--1.05)
   Other                                      1.38 (0.94--2.03)                 0.82 (0.66--1.03)
                                                                                         
  *Stage*                                                                    
   III                                             Referent                         Referent
   IV                                          0.95 (0.80--1.1)               1.22 (1.12--1.34)^\*^
                                                                                         
  *Histology*                                                                
   Serous                                          Referent                         Referent
   Mucinous                                   1.37 (0.89--2.09)               1.42 (1.13--1.78)^\*^
   Endometrioid                               0.80 (0.58--1.11)                 0.91 (0.77--1.08)
   Other                                      1.17 (0.96--1.42)                 1.08 (0.97--1.20)
                                                                                         
  *Live in a metropolitan area*                                              
   Yes                                             Referent                         Referent
   No                                         0.89 (0.65--1.24)                  1.1 (0.9--1.3)
                                                                                         
  *No. of comorbid conditions*                                               
   0                                               Referent                         Referent
   1                                          1.13 (0.92--1.37)                 1.08 (0.97--1.20)
   ⩾2                                       1.23 (0.99--1.52)^\*^             1.31 (1.17--1.47)^\*^
                                                                                         
  *SES*                                                                      
   Lowest quintile                                 Referent                         Referent
   Second quintile                            1.12 (0.85--1.48)                 1.01 (0.87--1.18)
   Third quintile                             1.13 (0.85--1.49)                 1.03 (0.89--1.20)
   Fourth quintile                            1.19 (0.89--1.58)                 0.93 (0.79--1.08)
   Fifth quintile                             1.09 (0.82--1.44)                 0.91 (0.79--1.06)
                                                                                         
  *Marital status*                                                           
   Yes                                             Referent                         Referent
   No                                       1.19 (1.00--1.42)^\*^               1.03 (0.94--1.13)
   Unknown                                    1.31 (0.78--2.19)                 0.96 (0.72--1.28)
                                                                                         
  *Teaching hospital*                                                        
   No                                              Referent                         Referent
   Yes                                        0.88 (0.71--1.09)               0.82 (0.73--0.92)^\*^

All variables controlled for each other, and year of diagnosis.

^\*^*P*\<0.01.

###### 

Univariate association between length of chemotherapy treatment (months) and demographic and clinical variables

                                     **⩽3 months**   **3--7 months**   **Total**                            
  --------------------------------- --------------- ----------------- ----------- -------- ------ --------- ------
                                          714            \(37\)          1218      \(63\)   1932   \(100\)   
  *Age at diagnosis*                                                                                        
   65--69                                 202            \(28\)           325      \(27\)   527    \(27\)    
   70--74                                 218            \(31\)           428      \(35\)   646    \(33\)    
   75--79                                 190            \(27\)           309      \(25\)   499    \(26\)    
   80+                                    104            \(15\)           156      \(13\)   260    \(13\)   0.20
                                                                                                             
  *Race*                                                                                                    
   White                                  648            \(91\)          1141      \(94\)   1789   \(93\)    
   Black                                  29              \(4\)           26       \(2\)     55     \(3\)    
   Other                                  37              \(5\)           51       \(4\)     88     \(5\)   0.03
                                                                                                             
  *Live in metropolitan location*                                                                           
   No                                     50              \(7\)           112      \(9\)    162     \(8\)    
   Yes                                    664            \(93\)          1106      \(91\)   1770   \(92\)   0.09
                                                                                                             
  *Marital status*                                                                                          
   No                                     341            \(48\)           531      \(44\)   872    \(45\)    
   Yes                                    350            \(49\)           652      \(54\)   1002   \(52\)    
   Unknown                                23              \(3\)           35       \(3\)     58     \(3\)   0.16
                                                                                                             
  *Teaching hospital*                                                                                       
   No                                     106            \(15\)           229      \(19\)   335    \(17\)    
   Yes                                    608            \(85\)           989      \(81\)   1597   \(83\)   0.03
                                                                                                             
  *Histology*                                                                                               
   Serous                                 449            \(63\)           776      \(64\)   1225   \(63\)    
   Mucinous                               13              \(2\)           35       \(3\)     48     \(2\)    
   Endometrioid                           60              \(8\)           97       \(8\)    157     \(8\)    
   Other                                  192            \(27\)           310      \(25\)   502    \(26\)   0.47
                                                                                                             
  *Stage*                                                                                                   
   III                                    447            \(63\)           775      \(64\)   1222   \(63\)    
   IV                                     267            \(37\)           443      \(36\)   710    \(37\)   0.65
                                                                                                             
  *No. of comorbid conditions*                                                                              
   0                                      357            \(50\)           646      \(53\)   1003   \(52\)    
   1                                      198            \(28\)           362      \(30\)   560    \(29\)    
   ⩾2                                     159            \(22\)           210      \(17\)   369    \(19\)   0.02
                                                                                                             
  *SES*                                                                                                     
   Lowest quintile                        131            \(18\)           208      \(17\)   339    \(18\)    
   Second quintile                        137            \(19\)           231      \(19\)   368    \(19\)    
   Third quintile                         154            \(22\)           239      \(20\)   393    \(20\)    
   Fourth quintile                        153            \(21\)           246      \(20\)   399    \(21\)    
   Fifth quintile                         139            \(19\)           294      \(24\)   433    \(22\)   0.20

###### 

Association of demographic and clinical characteristics with duration of chemotherapy ⩽3 months and mortality hazard ratios in patients with ovarian cancer by duration of chemotherapy

                                   **⩽3 months treatment**   **Overall mortality**
  ------------------------------- ------------------------- -----------------------
  *Length of treatment*                                     
   \<3 months                                ---                   Referent
   3--7 months                               ---             0.84 (0.75--0.94)^\*^
                                                                        
  *Age at diagnosis*                                        
   65--70                                 Referent                 Referent
   70--74                             1.23 (0.96--1.57)      1.29 (1.12--1.48)^\*^
   75--79                             1.02 (0.79--1.32)      1.29 (1.11--1.49)^\*^
   80+                                0.96 (0.70--1.32)      1.49 (1.25--1.79)^\*^
                                                                        
  *Race*                                                    
   White                                  Referent                 Referent
   Black                              0.60 (0.34--1.05)        0.83 (0.59--1.17)
   Hispanic                           2.30 (0.72--7.28)        1.24 (0.65--2.36)
   Other                              0.69 (0.43--1.13)        0.89 (0.66--1.20)
                                                                        
  *Stage*                                                   
   III                                    Referent                 Referent
   IV                                 0.97 (0.80--1.18)      1.26 (1.13--1.40)^\*^
                                                                        
  *Histology*                                               
   Serous                                 Referent                 Referent
   Mucinous                           1.71 (0.89--3.32)        0.95 (0.67--1.44)
   Endometrioid                       0.95 (0.67--1.35)        0.80 (0.65--0.98)
   Other                              0.92 (0.74--1.14)        1.01 (0.89--1.15)
                                                                        
  *Live in a metropolitan area*                             
   Yes                                    Referent                 Referent
   No                                 1.40 (0.96--2.04)        1.07 (0.86--1.32)
                                                                        
  *No. of comorbid conditions*                              
   0                                      Referent                 Referent
   1                                  1.05 (0.84--1.30)        1.12 (0.99--1.27)
   ⩾2                                 0.78 (0.61--1.00)      1.19 (1.03--1.36)^\*^
                                                                        
  *SES*                                                     
   Lowest quintile                        Referent                 Referent
   Second quintile                    1.08 (0.79--1.47)        1.04 (0.87--1.24)
   Third quintile                     1.02 (0.74--1.40)        1.17 (0.98--1.40)
   Fourth quintile                    1.05 (0.76--1.44)        0.94 (0.78--1.13)
   Fifth quintile                     1.36 (0.99--1.87)        0.93 (0.77--1.11)
                                                                        
  *Marital status*                                          
   Yes                                    Referent                 Referent
   No                                 0.88 (0.73--1.07)        1.10 (0.98--1.22)
   Unknown                            0.83 (0.48--1.43)        1.12 (0.81--1.55)
                                                                        
  *Teaching hospital*                                       
   No                                     Referent                 Referent
   Yes                                0.75 (0.58--0.97)      0.83 (0.73--0.96)^\*^

All variables controlled for each other and year of diagnosis.

^\*^*P*\<0.01.
